Lineage Cell Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $1.41M Beat $970.00K Estimate
Portfolio Pulse from saritha@benzinga.com
Lineage Cell Therapeutics (AMEX:LCTX) reported Q2 EPS of $(0.03), beating the $(0.04) estimate. Sales were $1.41M, surpassing the $970K estimate but down 56.34% from last year.
August 08, 2024 | 9:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lineage Cell Therapeutics reported better-than-expected Q2 EPS and sales, but sales were significantly down year-over-year.
The company beat both EPS and sales estimates, which is positive. However, the significant year-over-year decline in sales may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100